Aclaris Therapeutics (ACRS) Earnings Analysis

Aclaris Therapeutics (ACRS) next reports earnings on 2026-08-06, consensus EPS -0.16 USD. Last quarter (2026-05-07) it beat with EPS -0.15 USD vs -0.16 USD est (+6.3%). It has beaten estimates in 1/3 recent quarters (33%). Trailing P/E -10.04.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does ACRS next report earnings?

Next earnings date2026-08-06
Consensus EPS estimate-0.16 USD
Revenue estimate0.00B

ACRS earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-07-0.15 USD-0.16 USD+6.3%Beat
2026-02-26-0.16 USD-0.15 USD-6.7%Miss
2025-02-27-0.1 USD-0.09 USD-11.1%Miss

Beat rate: 1/3 (33%) over reported quarters with consensus data.

ACRS valuation and analyst view

Trailing P/E-10.04
Trailing EPS-0.54081 USD
Price / book5.04
Dividend yield0.00%
Market cap0.67B
Analyst consensusBuy (13 buy / 3 hold / 0 sell)
Avg price target11 USD

Related research pages

Frequently asked questions

When is Aclaris Therapeutics (ACRS)'s next earnings date?

Aclaris Therapeutics is next scheduled to report on 2026-08-06, with a consensus EPS estimate of -0.16 USD and revenue estimate of 0.00B.

Did ACRS beat earnings last quarter?

In its 2026-05-07 report, ACRS posted EPS of -0.15 USD versus a -0.16 USD estimate — a beat of 6.3%.

What is ACRS's earnings track record?

Over the last 3 reported quarters with consensus data, ACRS beat estimates 1 times (33%).

What is ACRS's current P/E ratio and EPS?

ACRS trades at a trailing P/E of -10.04 on trailing EPS of -0.5408118388277934 USD.

What do analysts rate ACRS?

Analyst consensus is "Buy" across 16 ratings (0 strong buy, 13 buy, 3 hold, 0 sell, 0 strong sell). Average 12-month price target: 11 USD.